Back to top
more

Halozyme Therapeutics (HALO)

(Real Time Quote from BATS)

$62.51 USD

62.51
328,756

+0.19 (0.31%)

Updated Aug 7, 2025 11:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.

Zacks Equity Research

CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected

by Zacks Equity Research

CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.

Zacks Equity Research

BioMarin (BMRN) Q2 Earnings & Sales Top Estimates, Ups '24 View

by Zacks Equity Research

BioMarin (BMRN) posts better-than-expected second quarter earnings. It also raises its revenue and earnings guidance for full-year 2024.

Zacks Equity Research

Curious about Halozyme Therapeutics (HALO) Q2 Performance? Explore Wall Street Estimates for Key Metrics

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Halozyme Therapeutics (HALO), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.

Zacks Equity Research

Bausch Health (BHC) Q2 Earnings In Line, Xifaxan Boosts Sales

by Zacks Equity Research

Bausch Health's (BHC) second-quarter adjusted earnings meet estimates while sales top the same, fueled by growth in Xifaxan sales.

Zacks Equity Research

Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat

by Zacks Equity Research

Blueprint Medicines' (BPMC) earnings and revenues surpass estimates in the second quarter of 2024. The company raises its product revenue guidance for 2024. Stock declines.

Zacks Equity Research

AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal

by Zacks Equity Research

Agios' (AGIO) second-quarter 2024 numbers miss estimates. Its sole-marketed drug fails to meet the primary endpoint of a late-stage label expansion study in pediatric patients with PK deficiency.

Zacks Equity Research

Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View

by Zacks Equity Research

Perrigo (PRGO) reports mixed second-quarter 2024 results. It cuts total net sales forecasts primarily due to expected lower distribution in U.S. store brand in second-half 2024.

Zacks Equity Research

Puma Biotechnology's (PBYI) Q2 Loss Narrower Than Expected

by Zacks Equity Research

Puma Biotechnology (PBYI) beats second-quarter estimates for both the top and the bottom line.

Zacks Equity Research

Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised

by Zacks Equity Research

Vertex (VRTX) incurs a wider-than-expected loss in the second quarter while sales come in line with estimates. Vertex raises its full-year product revenue guidance.

Zacks Equity Research

Amarin (AMRN) Stock Down Despite Q2 Earnings & Revenues Beat

by Zacks Equity Research

Amarin's (AMRN) second-quarter 2024 earnings and revenues beat estimates. Vascepa's sales in the United States decline year over year. Stock down.

Zacks Equity Research

Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash

by Zacks Equity Research

Moderna (MRNA) beats expectations for earnings and sales. Management cuts sales guidance by $0.5-$1.0 billion on concerns about competition for its marketed products and low sales in the EU.

Zacks Equity Research

JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View

by Zacks Equity Research

Jazz's (JAZZ) reports better-than-expected second quarter results. While it revises its guidance for 2024, it withdraws the financial guidance issued as part of the Vision 2025 plan.

Zacks Equity Research

Sage Therapeutics (SAGE) Q2 Loss Wider Than Expected, Sales Rise

by Zacks Equity Research

Sage Therapeutics (SAGE) incurs a wider-than-expected second-quarter 2024 loss. Collaboration revenues from Zurzuvae drive year-over-year revenue growth.

Zacks Equity Research

Repligen's (RGEN) Q2 Earnings & Revenues Meet Estimates

by Zacks Equity Research

Repligen's (RGEN) second-quarter earnings and revenues match estimates. The company narrows its revenue guidance for 2024. Stock rises.

Zacks Equity Research

United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates

by Zacks Equity Research

United Therapeutics (UTHR) reports mixed second-quarter 2024 results. Tyvaso sales continue to drive the company's top line.

Zacks Equity Research

Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View

by Zacks Equity Research

Merck (MRK) posts better than expected second-quarter results, backed by strong demand for blockbuster cancer drug Keytruda. The stock falls in pre-market trading, likely due to the EPS guidance slash.

Zacks Equity Research

Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates

by Zacks Equity Research

Corcept (CORT) beats on both earnings and sales in the second quarter of 2024. The company increases revenue guidance for 2024.

Zacks Equity Research

Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top

by Zacks Equity Research

Incyte's (INCY) second-quarter 2024 earnings miss estimates while revenues beat the same. The company raises the bottom end of the 2024 revenue guidance for its lead drug, Jakafi.

Zacks Equity Research

Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics

by Zacks Equity Research

Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics have been highlighted in this Industry Outlook article.

Ekta Bagri headshot

5 Biotech Stocks to Bet On Bright Industry Prospects

by Ekta Bagri

New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.

Zacks Equity Research

Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.

Zacks Equity Research

Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Equity Research

Zacks.com featured highlights include Amazon.com, Halozyme Therapeutics, Tenet Healthcare and Atmos Energy

by Zacks Equity Research

Amazon.com, Halozyme Therapeutics, Tenet Healthcare and Atmos Energy are part of the Zacks Screen of the Week article.